Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Read more at bms.com
Vice President, Bristol-Myers Squibb, Princeton, New Jersey + more
Vice President Research Collaborations at Bristol-Myers Squibb, Princeton, New Jersey
Principal Scientist and Alliance Manager at Bristol-Myers Squibb + more
Principal Scientist and Alliance Manager at Bristol-Myers Squibb
Executive Director, Business Operations, Research at Bristol-Myers Squibb + more
Marie Leithauser holds the position of Executive Director of Business Operations for Bristol-Myers Squibb's Research organization. She has served on the New Jersey Commission on Cancer Research and as a member of the State Theater's Education Committee.
Experience at Bristol-Myers Squibb:
* Chief of Staff for Senior Vice President, Research
* Focus Senior Team on high impact business issues and drive related strategy development
* String of Pearls integration planning
* Process simplification
Dr. Ruth Wexler joined the Bristol-Myers Squibb Company as Executive Director, Discovery Chemistry, (post-acquisition of DuPont Pharmaceuticals Company) and in the fall of 2002, she moved to Hopewell site in New Jersey where she currently heads the medicinal chemistry efforts directed at Cardiovascular Diseases.
She was honored in 2004 as one of twelve Outstanding New Jersey Women in Research by the New Jersey Association for Biomedical Research. In 2011, she was a recipient of the Bristol-Myers Squibb Ondetti and Cushman award for her leadership role in the discovery of Eliquis®. She has been selected as the recipient of the 2015 E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances. Ruth has co-authored over 190 peer-reviewed scientific publications and patents, and has contributed several review articles and book chapters largely in the area of cardiovascular research.
Creative, results-oriented, passionate, and strategic R&D leader with expertise that spans the gamut from Process Development to Medicinal Chemistry and from Alliance Management to Business Development. Scientifically-driven business professional with strong interpersonal, communication, consulting, and project management skills.
A proven leader of multi-disciplinary teams across functional areas who has contributed to the nomination of five (5) clinical candidates throughout his tenure within six (6) Therapeutic Areas within Discovery and the advancement of two (2) candidates within Process Development. Current Lead within Research Collaborations for Fibrosis, Immunoscience, Virology, and Discovery Platforms who not only manages established relationships, but also works closely with R&D senior management, corporate BD, Finance, and Legal to seek out new business opportunities and alliances. A leader of the organization’s strategic in-licensing and out-licensing activities.
VP, Molecular Discovery Technologies, Bristol-Myers Squibb + more
Dr. Sharon Cload, served as Vice President of Research at Adnexus Therapeutics, Inc. and served as Vice President of Discovery of Adnexus Therapeutics Inc. since July 2008. Dr. Cload has more than a decade of experience in lead discovery and managing biotech-pharma partnerships. Prior to joining Adnexus, she spent seven years in lead discovery and technology development at Archemix Corp., most recently as Vice President, Aptamer Discovery. From 1996 to 2000, Dr. Cload developed small molecule discovery technologies for both RNA and protein targets at Anadys Pharmaceuticals (formerly Scriptgen Pharmaceuticals), a biotechnology company. Dr. Cload holds a Ph.D. in Bio-Organic chemistry from Yale University, and was an NIH post-doctoral fellow with Peter Schultz at the University of California, Berkeley. Dr. Cload received her BA in Chemistry at New College of the University of South Florida.
Head of Discovery Chemistry, Bristol-Myers Squibb + more